Consistently, IL-6 blockade treatment significantly improved animal survival time by 35% in our genetically engineered GBM model (17 versus 23 days, in control and anti-IL-6 antibody-treated mice, Supplementary Fig. 18). The gene discussed is IL6; the disease is glioblastoma.